Xeroderma pigmentosum: Research & Drug Discovery Data

Drug discovery

drugs

With orphan designations

Overview

Xeroderma pigmentosum (XP) is a rare autosomal recessive disorder characterized by defective DNA repair mechanisms, leading to extreme photosensitivity, UV-induced skin cancers (10,000× higher risk), ocular damage, and progressive neurodegeneration in 20-30% of cases. Symptoms manifest in infancy with severe sunburns, freckling, and premature skin aging. Diagnosis relies on clinical features and genetic testing. Management focuses on rigorous UV avoidance, frequent cancer surveillance, and prompt lesion treatment. Median survival is 32 years, with metastatic skin cancer as the leading cause of death [1][4][11].

Population

Affects 1 in 1 million in the US/Europe, with higher prevalence in Japan (1:20,000), North Africa, and consanguineous communities. Carrier rates reach 1:113 in Japanese populations (XPA-related) [1][7][12].

Burden

60% mortality before age 20; median lifespan 32 years [4][11].
Neurological decline (ataxia, dementia) affects 25-30%, worsening prognosis [1][12].
95% develop skin cancer by age 14 without protection, with 50-fold increased CNS cancer risk [4][14].

Therapies

Strict UV avoidance: Protective clothing, UV-blocking films, and sunscreen [5][11].
Early cancer intervention: Surgical excision, photodynamic therapy, and topical 5-fluorouracil/imiquimod [3][5][10].
Investigational approaches: Oral retinoids, nicotinamide, and gene therapy (preclinical) [5][13].

Categories: rare developmental anomalies during embryogenesis, rare genetic diseases, rare neoplastic diseases, rare neurological diseases, rare ophthalmic disorders, rare skin diseases

Research Papers

1,221 drug discovery papers related to Xeroderma pigmentosum, with 5 first-in-class and 1 next-in-class early-stage therapies forecasted to outperform the average preclinical success rate. Recent publications:

2026-07-10 | Supplementary Material for: Novel variant and a possible new founder effect for Xeroderma Pigmentosum variant type in Southeast Brazil: Case Report

Introduction: Xeroderma pigmentosum (XP) is a group of genodermatoses with autosomal recessive inheritance, comprising 9 subtypes designated A to J plus a variant (V) type, clinically characterized by increased photosensitivity, with specific subtypes more prone to ocular disease and progressive neurodegeneration. Case presentation: Three patients with the XP-V variant, a pair of sisters and an unrelated individual, presented with a novel homozygous c.1245-1G>A intronic splice site variant in the POLH gene classified as likely pathogenic. They exhibited numerous freckles and hypo- and hyperpigmented lesions that evolved into basal cell and squamous cell carcinomas, as well as thin malignant melanocytic lesions, photophobia, conjunctival telangiectasis, ectropion, and pterygia, without neurological symptoms. Conclusion: The possibility of dealing with a new founder effect for this specific variant in the State of Minas Gerais, in the Southeast region of Brazil, is suggested.

Open article ↗

2026-07-01 | Xeroderma pigmentosa with corneal involvement

Xeroderma pigmentosum (XP) is a rare autosomal recessive disorder characterized by defective DNA repair, leading to extreme sensitivity to ultraviolet radiation and a high risk of cutaneous and ocular malignancies. This case report presents a case of a 14-year-old boy with XP who experienced photophobia along with significant ocular surface squamous neoplasia (OSSN). The patient’s family history indicated hereditary involvement. Ocular examination revealed OSSN, treated with topical 1% 5-fluorouracil (5-FU) four times daily for 1 week, followed by a 3-week drug holiday, repeated for three cycles. Significant improvement was observed in tumor size and ocular symptoms post-treatment. This case report highlights the effectiveness of 5-FU as a noninvasive, cost-effective alternative to other chemotherapeutic agents and surgical excision in managing OSSN in XP patients, emphasizing the importance of tailored treatment strategies and the necessity of long-term monitoring due to the ongoing risk of recurrence and malignancy.

Open article ↗

2026-07-10 | Supplementary Material for: Novel variant and a possible new founder effect for Xeroderma Pigmentosum variant type in Southeast Brazil: Case Report

Open article ↗

2026-07-01 | Xeroderma pigmentosa with corneal involvement

Open article ↗

Access all drug discovery articles and probability of success in trials forecasts:

Request access

Drug Discovery Landscape

4 orphan drug designations for Xeroderma pigmentosum.

Drug	Therapy type	Regulator	Orphan designation	Approval	Sponsor
Afamelanotide	peptides	EMA	2024-05-24	—	Clinuvel Europe Limited
Pro-Pro-Thr-Val-Pro-Thr-Arg	peptides	FDA	2017-07-27	—	ProGeLife S.A.S
PRO-PRO-THR-VAL-PRO-THR-ARG [INHOX]	peptides	EMA	2014-11-19	—	ProGeLife S.A.S.
T4 endonuclease V, liposome encapsulated	proteins	FDA	1989-06-27	—	AGI Dermatics

Xeroderma pigmentosum

Xeroderma pigmentosum

Xeroderma pigmentosum

Overview

Population

Burden

Therapies

Categories: rare developmental anomalies during embryogenesis, rare genetic diseases, rare neoplastic diseases, rare neurological diseases, rare ophthalmic disorders, rare skin diseases

Research Papers

2026-07-10 | Supplementary Material for: Novel variant and a possible new founder effect for Xeroderma Pigmentosum variant type in Southeast Brazil: Case Report

2026-07-01 | Xeroderma pigmentosa with corneal involvement

2026-07-10 | Supplementary Material for: Novel variant and a possible new founder effect for Xeroderma Pigmentosum variant type in Southeast Brazil: Case Report

2026-07-01 | Xeroderma pigmentosa with corneal involvement

Drug Discovery Landscape

Updated: Jul 31, 2026